Hepatitis B Virus Reactivation in COVID-19

University Medical Centre Ljubljana1,793 enrolled

Overview

The aim of this observational cohort study was to evaluate adherence to hepatitis B virus (HBV) screening guidelines in a country characterized by low HBV prevalence and assess the potential reactivation and progression of HBV infection in anti-HBV core antigen antibodies (anti-HBc) positive patients receiving corticosteroids for coronavirus disease 2019 (COVID-19).

Study Type

OBSERVATIONAL

Enrollment

1,793

Conditions

COVID-19 Pneumonia Hypoxemia Hepatitis B

Interventions

Hepatitis B virus infectionDIAGNOSTIC_TEST

anti-hepatitis B virus core antigen positive serologic status

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * hospitalized adult patients with a positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ribonucleic acid (RNA) polymerase chain reaction (PCR) test * supplemental oxygen * treated with corticosteroids for COVID-19 pneumonia Exclusion Criteria: * age under 18 years * hospitalized for medical conditions unrelated to COVID-19 * received corticosteroid therapy for non-COVID-19 reasons

Locations (1)

University Medical Centre Ljubljana

Ljubljana, Slovenia

Outcomes

Primary Outcomes

HBV reactivation

number (%) of patients with HBV reactivation

Time frame: at least 3 months post treatment with corticosteroids

number (%) of patients with HBV reactivation

Time frame: one year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.